RUTW241216C2735000
- 0.00
- 0.000.00%
Russell 2000 Index Newsroom
D. Boral Capital Maintains Outperform on ICF International, Maintains $174 Price Target
ICF International Analyst Ratings
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
Summit Therapeutics Shares Are Trading Higher. The Stock May Be Moving in Sympathy With Neurocrine Biosciences Which Received FDA Approval for CRESNESSITY.
Looking At Cleanspark's Recent Unusual Options Activity
Expert Outlook: StoneCo Through The Eyes Of 4 Analysts
Worst Performing Stocks for Tax Loss Selling – Wolfe
A Look Into NEXTracker Inc's Price Over Earnings
Par Pacific Shares Are Trading Lower After Mizuho Downgraded Its Rating on the Stock From Outperform to Neutral and Lowered Its Price Target From $26 to $22.
Watching Summit Therapeutics; Traders Circulate Newsletter Mention
Foghorn Therapeutics Analyst Ratings
10 Analysts Have This To Say About Xometry
Assessing CarGurus: Insights From 11 Financial Analysts
As US Faces Shortage Of Expensive Skilled Clinicians, Home-Based Health Service Provider Addus HomeCare Is Well-Positioned To Grow: Analyst
Broadcom, Tesla Propel Nasdaq 100 Gains, Bitcoin Hits $107,000, Fueling Crypto Stocks Rally: What's Driving Markets Monday?
Four Hidden Gems in the Stock Market From a Five-star Fund Manager
What's Going On With MARA Shares Monday?
A Look Into REV Group Inc's Price Over Earnings
Forecasting The Future: 10 Analyst Projections For Agilon Health
8 Breakout Stocks to Watch – EA, FLUT, COMP, NET, and Others